ANALYZING EFFICACY OF INTRAVITRIAL DICLOFENAC VERSUS INTRAVITRIAL BEVACIZUMAB IN IMPROVING PATHOPHYSIOLOGY OF DIABETIC MACULAR OEDEMA
Aim: The aim of the study was to compare the efficacy of intravitreal Diclofenac (IV-D) with bevacizumab (IV-B) in improving pathophysiology of diabetic macular edema (DME).
Material and Methods: In this comparative case series interventional study, 50 eyes from 25 patients with bilateral diabetic macular edema were selected and randomly allocated to either intravitreal diclofenac or bevacizumab with exclusion and inclusion criteria devised for the study participants. The participants were observed for 24 weeks (6 months) for any improvement in best corrected visual acuity (BCVA) and central macular thickness by spectral domain OCT, the patients were also evaluated for intraocular pressure (IOP).
Results: Fifty eyes of 25 patients were analyzed. 25 eyes were given intravitreal diclofenac 500µg/0.1ml, while 25 eyes received 1.25mg/0.05ml bevacizumab. After 6 months of follow up, there was improvement in the visual acuity from 0.54 ± 0.11 in IV-B and 0.56 ± 0.13 LogMAR in IV-D before injections to 0.24 ± 0.13 and 0.28 ± 0.10 respectively. In both groups marked reduction in CMT from baseline was observed but there was no statistically significant difference noted between the groups. Interestingly in IV-D, but not IV-B, decreased intraocular pressure (IOP) was noted, achieving statistically significant level. No adverse injections related side effects were observed. (Endophthalmitis, intra-ocular inflammation and cataract).
Conclusion: This study showed that intravitreal diclofenac (IV-D) by virtue of its anti-inflammatory properties showed improvement both in terms of visual acuity as well as reduction of the central macular thickness almost similar to bevacizumab but without any side effects of steroids.